Reuters logo
BRIEF-Puma's investigational drug PB272 was presented at the 2016 San Antonio Breast Cancer Symposium
December 8, 2016 / 1:32 AM / a year ago

BRIEF-Puma's investigational drug PB272 was presented at the 2016 San Antonio Breast Cancer Symposium

Dec 7 (Reuters) - Puma Biotechnology Inc

* Puma Biotechnology - Median p95HER2 levels were higher in samples from patients who achieved a pCR with neratinib

* Puma Biotechnology presents results of biomarker analysis of Phase II trial of PB272 in Neoadjuvant Treatment of HER2-positive locally advanced breast cancer at the 2016 San Antonio Breast Cancer Symposium Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below